Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €10.65 EUR
Change Today +0.096 / 0.91%
Volume 1.4K
As of 3:44 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

raptor pharmaceutical corp (XYXR) Snapshot

Open
€10.55
Previous Close
€10.55
Day High
€11.11
Day Low
€10.43
52 Week High
03/13/15 - €11.36
52 Week Low
06/4/14 - €5.69
Market Cap
857.0M
Average Volume 10 Days
1.6K
EPS TTM
--
Shares Outstanding
80.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RAPTOR PHARMACEUTICAL CORP (XYXR)

raptor pharmaceutical corp (XYXR) Related Bloomberg News

View More Bloomberg News

raptor pharmaceutical corp (XYXR) Related Businessweek News

No Related Businessweek News Found

raptor pharmaceutical corp (XYXR) Details

Raptor Pharmaceutical Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The company offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults, as well as in six years and older children in the United States, in the 28 member states of the European Union, Norway, Liechtenstein, and Iceland. Its clinical development programs include RP103 that is used as a treatment for Huntington's disease; RP103 as a treatment for non-alcoholic fatty liver disease in children; and RP103 as a treatment for mitochondrial disorders, including Leigh syndrome. The company’s other clinical-stage product candidates comprise Convivia, an oral formulation of 4-methylpyrazole for the treatment of acetaldehyde toxicity resulting from aldehyde dehydrogenase deficiency. Its preclinical product candidates include cysteamine dioxygenase and HepTide for the treatment of hepatocellular carcinoma and other cancers susceptible to induced lysosomal storage. Raptor Pharmaceuticals Corp. has a collaboration agreement with DaVita Clinical Research to screen blood samples from the United States patients with end-stage renal disease to identify patients with unrecognized late-onset nephropathic cystinosis. The company was founded in 2005 and is headquartered in Novato, California.

123 Employees
Last Reported Date: 03/2/15
Founded in 2005

raptor pharmaceutical corp (XYXR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $421.1K
Chief Business Officer
Total Annual Compensation: $305.9K
Chief Commercial Officer
Total Annual Compensation: $114.9K
Corporate Controller
Total Annual Compensation: $210.8K
Compensation as of Fiscal Year 2014.

raptor pharmaceutical corp (XYXR) Key Developments

Raptor Pharmaceuticals Corp. Approves Amendment to the Bylaws and Restated Bylaws

On and effective as of May 18, 2015, the Board of Directors of Raptor Pharmaceutical Corp. approved an amendment to the Bylaws of the Company. In addition, on May 18, 2015, the Board approved the amended and restated Bylaws of the Company, effective as of immediately following the 2015 annual meeting of stockholders.

Raptor Pharmaceuticals Corp. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Full Year 2015

Raptor Pharmaceuticals Corp. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company announced revenues of $20,453,000 compared to $12,134,000 for the same period a year ago. Loss from operations was $14,660,000 compared to $10,791,000 for the same period a year ago. Net loss before provision for income taxes was $19,662,000 compared to $14,885,000 for the same period a year ago. Net loss was $19,683,000 compared to $14,891,000 for the same period a year ago. Net loss per share, basic and diluted was $0.28 compared to $0.24 for the same period a year ago. Non-GAAP loss was $16,830,000 compared to $12,516,000 for the same period a year ago. Non-GAAP net loss per share, basic and diluted was $0.24 compared to $0.20 for the same period a year ago. For 2015, the company expects maintaining worldwide PROCYSBI sales guidance of $80 million to $90 million. The company also continue to be on track for investment in operational spending for the year and are reiterating non-GAAP operating guidance -- non-GAAP operating expense guidance between $115 million and $125 million.

Raptor Pharmaceuticals Corp. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 01:00 PM

Raptor Pharmaceuticals Corp. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 01:00 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Julie Anne Smith, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XYXR:GR €10.65 EUR +0.096

XYXR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $42.50 USD +0.18
Illumina Inc $205.00 USD +1.88
View Industry Companies
 

Industry Analysis

XYXR

Industry Average

Valuation XYXR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.6x
Price/Book 24.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RAPTOR PHARMACEUTICAL CORP, please visit www.raptorpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.